- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- open-label rifaximin, double-blind placebo, double-blind rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 293
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 1,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- Soluble protein hydrolysate (SPHi)
- Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab (D2E7)
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 43
- States / cities
- Berkeley, California • Long Beach, California • San Diego, California + 37 more
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- Tenapanor, Placebo
- Drug
- Lead sponsor
- Ardelyx
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 15 more
- Conditions
- IBD, Ulcerative Colitis, Crohn Disease
- Interventions
- Vitamin D3
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 7 Years to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ulcerative Colitis
- Interventions
- Etrolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • La Jolla, California • Orange, California + 51 more
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, CD
- Interventions
- Bacteriotherapy
- Biological
- Lead sponsor
- David Suskind
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 11
- States / cities
- San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Not listed
- Lead sponsor
- CorEvitas
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2100
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Crohn's Disease
- Interventions
- Teduglutide (ALX-0600)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Lakewood, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Crohn's Disease, Active
- Interventions
- Partial enteral nutrition - orally consumed formula
- Dietary Supplement
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- Placebo, HE3286
- Drug
- Lead sponsor
- Harbor Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
- Conditions
- Interstitial Cystitis, Irritable Bowel Syndrome
- Interventions
- Not listed
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Irritable Bowel Syndrome
- Interventions
- curcumin, placebo
- Dietary Supplement
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Crohn's Disease
- Interventions
- STA-5326
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Crohn Disease of Small Intestine
- Interventions
- Vedolizumab 300 MG Injection [Entyvio]
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Inflammatory Disease, Permeability; Increased, Crohn Disease, Inflammatory Bowel Diseases, Environmental Enteropathy
- Interventions
- IPD Probe via TNIT
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Moderately to Severely Active Crohn Disease
- Interventions
- Obefazimod, Placebo
- Drug · Other
- Lead sponsor
- Abivax S.A.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 43
- States / cities
- Fairhope, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
- Conditions
- Ulcerative Colitis
- Interventions
- Tilpisertib, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 23
- States / cities
- Dothan, Alabama • Lancaster, California • Murrieta, California + 20 more
- Conditions
- Crohn's Disease
- Interventions
- infliximab, placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- MK-6194, MK-6194-matching placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Rialto, California • Kissimmee, Florida • Raleigh, North Carolina + 1 more
- Conditions
- Ulcerative Colitis
- Interventions
- SHR0302, Placebo
- Drug
- Lead sponsor
- Reistone Biopharma Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 46
- States / cities
- Huntsville, Alabama • Roseville, California • San Diego, California + 41 more
- Conditions
- Ulcerative Colitis
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Stanford, California